-
Oral rofecoxib (Vioxx) may have a role in controlling postoperative pain patients undergoing knee surgery.
-
-
A new, and as of yet unpublished study, has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events.
-
-
Sources of funding for pharmaceutical research has come under scrutiny in the last decade as academic and government sources of funding have become increasingly scarce and the pharmaceutical industry has become the main source of research dollars. But the issue of objectivity has been raised, and some have even suggested that negative studies, that is studies that show a drug in an unfavorable light, may never be published. The American Medical Association has recently tackled this issue and has asked the department of Health and Human Services to establish a public registry of all clinical trials in United States.
-
End-stage renal disease is a devastating condition that, according to the United States Renal Data System, plagued approximately 406,000 individuals in the United States in 2001 and is projected to increase to a prevalence of approximately 725,000 by 2010. Furthermore, it is a major public health issue, given the overall poor outcomes and high costs for this chronic condition.
-
-
When it comes to treating lipids in patients with heart disease, the mantra may be, The lower the LDL, the better. Data from the multicenter Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial indicate that aggressive reduction of atherogenic lipoproteins prevents progression of disease.
-
-
Physicians increasingly are aware of the need to provide prophylaxis against venous thrombosis for the medically ill patient in the hospital environment. This article attempts to separate the fact from fiction regarding VTE prophylaxis.